Skip to main content
SpringerLink
Log in

Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma

  • Adis Drug Evaluation
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Oral panobinostat (Farydak®), a potent nonselective histone deacetylase inhibitor, is approved in several countries for use in combination with bortezomib and dexamethasone in patients with multiple myeloma (MM) [USA] or relapsed and/or refractory MM (EU) who have received at least two prior treatment regimens, including bortezomib and an immunomodulatory drug (IMiD). In a pivotal phase III trial (PANORAMA 1) in patients with relapsed or relapsed and refractory MM who had received one to three previous lines of therapy, progression-free survival (PFS) was significantly prolonged with panobinostat plus bortezomib and dexamethasone compared with placebo plus bortezomib and dexamethasone. The significantly favourable effect of panobinostat- versus placebo-based treatment on PFS was also observed in a subgroup analysis of patients who had previously received an IMiD, bortezomib plus an IMiD, or at least two lines of treatment including bortezomib and an IMiD. Panobinostat plus bortezomib and dexamethasone had a generally manageable tolerability profile, with the most frequent grade 3–4 adverse events being myelosuppression, diarrhoea, asthenia or fatigue, peripheral neuropathy and pneumonia. Thus, panobinostat, in combination with bortezomib and dexamethasone, is a useful addition to the available treatment options for patients with relapsed or refractory MM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Anderson KC, Alsina M, Atanackovic D. National Comprehensive Cancer Network clinical practice guidelines in oncology: multiplemyeloma, version 2.2016. 2015. http://www.nccn.org/patients. Accessed 11 Dec 2015.

  2. Richardson PG, Laubach JP, Lonial S, et al. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Rev Anticancer Ther. 2015;15(7):737–48.

    Article  CAS  PubMed  Google Scholar 

  3. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia. 2012;26(1):149–57.

    Article  CAS  PubMed  Google Scholar 

  4. Laubach JP, Voorhees PM, Hassoun H, et al. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol. 2014;7(1):97–111.

    Article  CAS  PubMed  Google Scholar 

  5. Torimoto Y, Shindo M, Ikuta K, et al. Current therapeutic strategies for multiple myeloma. Int J Clin Oncol. 2015;20(3):423–30.

    Article  CAS  PubMed  Google Scholar 

  6. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009;280(2):233–41.

    Article  CAS  PubMed  Google Scholar 

  7. Mithraprabhu S, Kalff A, Chow A, et al. Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics. 2014;9(11):1511–20.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Richardson PG, Mitsiades CS, Laubach JP, et al. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors inmultiplemyeloma. Leuk Res. 2013;37(7):829–37.

    Article  CAS  PubMed  Google Scholar 

  9. Novartis Pharmaceuticals Corporation. Farydak® (panobinostat) capsules, for oral use: US prescribing information. 2015. http://www.fda.gov. Accessed 11 Dec 2015.

  10. Novartis Europharm Limited. Farydak hard capsules: EU summary of product characteristics. 2015. http://ema.europa.eu. Accessed 11 Dec 2015.

  11. Novartis AG. Novartis Pharmaceuticals corporate fact sheet. 2015. http://www.novartis.com. Accessed 11 Dec 2015.

  12. Rajkumar SV. Panobinostat for the treatment of multiple myeloma. Lancet Oncol. 2014;15(11):1178–9.

    Article  CAS  PubMed  Google Scholar 

  13. Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alphatubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108(10):3441–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Maiso P, Carvajal-Vergara X, Ocio EM, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res. 2006;66(11):5781–9.

    Article  CAS  PubMed  Google Scholar 

  15. Ocio EM, Vilanova D, Atadja P, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010;95(5):794–803.

    Article  CAS  PubMed  Google Scholar 

  16. San-Miguel JF, Richardson PG, Günther A, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013;31(29):3696–703.

    Article  CAS  PubMed  Google Scholar 

  17. San-Miguel JF, Hungria VTM, Yoon S-S, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractorymultiplemyeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–206.

    Article  CAS  PubMed  Google Scholar 

  18. Richardson PG, Hungria VTM, Yoon S-S, et al. Panobinostat plus bortezomib and dexamethasone in relapsed/relapsed and refractory myeloma: outcomes by prior treatment. Blood. 2015. doi:10.1182/blood-2015-09-665018.

    Google Scholar 

  19. Wolf JL, Siegel D, Goldschmidt H, et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012;53(9):1820–3.

    Article  CAS  PubMed  Google Scholar 

  20. Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomibrefractory myeloma. Blood. 2013;122(14):2331–7.

    Article  CAS  PubMed  Google Scholar 

  21. Moreau P, San Miguel J, Ludwig H. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):vi133–7.

    PubMed  Google Scholar 

  22. Niesvizky R, Ely S, Mark T, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractorymultiple myeloma. Cancer. 2011;117(2):336–42.

    Article  CAS  PubMed  Google Scholar 

  23. Richardson P, Mitsiades C, Colson K, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008;49(3):502–7.

    Article  CAS  PubMed  Google Scholar 

  24. US Food and Drug Administration. FDA approves Farydak for treatment of multiple myeloma [media release]. 23 Feb 2015. http://www.fda.gov.

  25. Novartis AG. Novartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myeloma [media release]. 23 Feb 2015. http://www.novartis.com.

  26. Novartis AG. Novartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multiple myeloma [media release]. 4 Sep 2015. http://www.novartis.com.

  27. Dimopoulos M, Siegel DS, Lonial S, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, doubleblind study. Lancet Oncol. 2013;14(11):1129–40.

    Article  CAS  PubMed  Google Scholar 

  28. Berdeja JG, Hart LL, Mace JR, et al. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica. 2015;100(5):670–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Chari A, Cho HJ, Parekh S, et al. A phase II, single-center, open-label study of oral panobinostat in combination with lenalidomide and weekly dexamethasone in patients with multiple myeloma [abstract]. Blood. 2014;124(21):3486.

    Google Scholar 

  30. Popat R, Brown S, Flanagan LM, et al. Velcade, thalidomide, dexamethasone and panobinostat (VTD-P) for patients with relapsed and relapsed/refractory myeloma: preliminary results of the Muk-Six phase I/IIa trial [abstract]. Blood. 2014;124(21):4766.

    Google Scholar 

  31. Berenson JR, Hilger JD, Yellin O, et al. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Ann Hematol. 2014;93(1):89–98.

    Article  CAS  PubMed  Google Scholar 

  32. Offidani M, Polloni C, Cavallo F, et al. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractorymultiplemyeloma. Leuk Lymphoma. 2012;53(9):1722–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

During the peer review process, the manufacturer of panobinostat was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Sarah L. Greig

Authors
  1. Sarah L. Greig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah L. Greig.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of Interest

Sarah Greig is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

The manuscript was reviewed by: M. Beksac, Department of Hematology, Faculty of Medicine, Ankara University, Ankara, Turkey; S. Jagannath, The Tisch Cancer Institute, Mount Sinai Hospital, New York, NY, USA; E. M. Ocio, Complejo Asistencial Universitario de Salamanca (IBSAL), Centro Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain; A Palumbo, Division of Haematology, University of Torino, Torino, Italy; G. Pratt, School of Cancer Sciences, University of Birmingham, Heart of England NHS Foundation Trust, Birmingham, UK.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Greig, S.L. Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma. Targ Oncol 11, 107–114 (2016). https://doi.org/10.1007/s11523-015-0413-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-015-0413-6

Keywords

Search

Navigation